source
- Tempus AI to buy cancer test maker Personalis for $1.5 billionTempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
- UK regulator reports rise in drug approvals and new AI healthcare regulationsThe UK's Medicines and Healthcare products Regulatory Agency (MHRA) released its 2025-2026 annual report to Parliament. The agency highlighted that it approved more new medicines in the past year…